Quick Recap
Obstetrics System, Protocol 2/6. Closely related to Eclampsia (prior protocol) — shares the magnesium sulfate seizure prophylaxis and BP management framework; this protocol focuses on the distinct hepatic/hematologic syndrome and its specific delivery-timing and platelet-transfusion decision points.
1. Definition
HELLP = Hemolysis, Elevated Liver enzymes, Low Platelets — a severe variant/complication of preeclampsia, though it can occasionally occur without the classic hypertension/proteinuria being fully expressed. Complicates 4-12% of patients with severe preeclampsia.
2. Clinical Presentation
Signs/symptoms: right upper quadrant or epigastric pain, nausea and vomiting, malaise, and NONSPECIFIC viral-like symptoms — this nonspecific presentation is a genuine diagnostic trap, since a pregnant patient presenting with RUQ pain, nausea, and malaise can easily be mistaken for a primary GI illness (gastroenteritis, cholecystitis) rather than recognized as an obstetric emergency; maintain a high index of suspicion in any pregnant/postpartum patient with this symptom cluster, especially with known or developing hypertension.
Physical exam: RUQ or epigastric tenderness, generalized edema.
Hepatic hemorrhage/rupture: rare but catastrophic (see Eclampsia protocol Section 2) — hepatic capsule irritation from subcapsular hematoma causes the RUQ pain; sudden severe pain with hemodynamic instability should raise concern for rupture.
3. Diagnostic Criteria (Laboratory-Based)
Hemolysis (schistocytes on peripheral smear, elevated LDH, low haptoglobin, indirect hyperbilirubinemia), elevated liver enzymes (AST/ALT), thrombocytopenia (platelet count <100,000/mm3, with severity grading by some classification systems further stratifying by count). HELLP represents a thrombotic microangiopathy overlapping mechanistically with the broader preeclampsia/eclampsia spectrum — apply the same shared pathophysiologic framework (vasospasm, endothelial dysfunction, microvascular injury) used for preeclampsia generally.
4. Immediate Stabilization (ABCDE)
Apply the SAME general stabilization framework as the Eclampsia protocol: anticipate difficult airway with senior-clinician intubation if needed, two large-bore IVs, Foley catheter, judicious (not aggressive) fluid management, left lateral positioning to prevent supine hypotension syndrome, and magnesium sulfate for seizure prophylaxis during labor and for 24 hours postpartum — HELLP patients receive the same magnesium-based seizure prophylaxis as severe preeclampsia/eclampsia patients even without an eclamptic seizure having occurred, given the shared disease spectrum and seizure risk.
Checklist:
5. Delivery Timing — Gestational-Age-Dependent Pathway
Delivery is the definitive treatment for HELLP syndrome (same principle as preeclampsia/eclampsia generally).
>=34 weeks gestation: delivery is indicated — do not delay for further fetal maturation given the maternal risk profile at this stage.
<34 weeks gestation: delivery MAY be delayed to allow a corticosteroid course for fetal lung maturity — betamethasone 12mg IM every 24 hours x2 doses, with delivery planned 24 hours after the LAST dose — this deliberate, time-limited delay balances fetal benefit against maternal risk, and requires close multidisciplinary (maternal-fetal medicine, neonatology) monitoring throughout the delay window given HELLP's potential for rapid deterioration.
During labor and for 24h postpartum: magnesium sulfate for seizure prophylaxis regardless of the delivery timing pathway chosen.
6. Platelet Transfusion Thresholds — Distinct from General ICU Practice
Transfuse platelets when the count is <20,000/mm3 (a lower threshold than many general ICU bleeding-risk contexts, reflecting HELLP's typically self-limited postpartum thrombocytopenia trajectory once delivery occurs).
For CESAREAN delivery, OR with any significant bleeding: transfuse platelets if count is <50,000/mm3 — the higher threshold specifically for surgical/bleeding scenarios reflects the increased hemostatic demand of operative delivery or active hemorrhage, distinct from the lower prophylactic threshold used for a stable, non-bleeding, non-operative patient.
This two-tiered threshold (20K general vs 50K surgical/bleeding) is the key practical decision point distinguishing HELLP platelet management from a single fixed number — apply the context-appropriate threshold rather than a blanket rule.
7. Investigations
CBC with peripheral smear (schistocytes, platelet count), LDH, haptoglobin, indirect bilirubin, AST/ALT, coagulation panel (PT/INR/aPTT/fibrinogen — screen for concurrent DIC, which can complicate severe HELLP), renal function, urinalysis for proteinuria, fetal heart rate monitoring and ultrasound, imaging (ultrasound or CT) if hepatic rupture/subcapsular hematoma is suspected based on severe RUQ pain and hemodynamic instability.
8. Organ Support
Magnesium sulfate seizure prophylaxis per the Eclampsia protocol; BP management per the same 15-25% MAP reduction target; judicious fluid management; platelet transfusion per the two-tiered threshold above; blood product support for hemorrhage if hepatic rupture or DIC develops; standard ICU supportive care; multidisciplinary delivery planning per gestational age.
9. Consultation Matrix
Consultation | Trigger | Timing |
Obstetrics/Maternal-Fetal Medicine | All HELLP syndrome | Immediate, multidisciplinary |
Hematology | Severe thrombocytopenia, concurrent DIC, transfusion management | As needed |
General/Hepatobiliary Surgery | Suspected hepatic rupture/subcapsular hematoma | Immediate if suspected |
Neonatology | Anticipated preterm delivery, especially during a corticosteroid-delay window <34 weeks | Immediate |
10. Monitoring Framework
Serial CBC/platelet count, LDH/haptoglobin/bilirubin trend, AST/ALT trend, coagulation panel (DIC surveillance), BP monitoring per the Eclampsia protocol framework, magnesium toxicity surveillance (DTR/respiratory status) if on magnesium infusion, fetal monitoring throughout any delayed-delivery window.
11. Complications
Hepatic hemorrhage/rupture (rare, catastrophic), DIC, progression to eclampsia, acute renal failure, pulmonary edema, abruptio placentae, fetal complications from prematurity or placental insufficiency. Prevention: prompt recognition despite the nonspecific presentation, appropriate gestational-age-based delivery timing, context-appropriate platelet transfusion thresholds. Rescue: emergency delivery for maternal deterioration, surgical management for hepatic rupture, standard DIC/hemorrhage management, magnesium toxicity reversal with calcium gluconate if needed.
12. Escalation & De-escalation
Escalate: hepatic rupture suspected (severe RUQ pain + instability) -> emergent imaging and surgical consultation; progression to eclampsia or DIC -> full Eclampsia protocol escalation plus DIC management.
De-escalate: delivered, platelet count/LDH/liver enzymes trending toward normal (typically resolving within days postpartum), magnesium course completed -> transition to standard postpartum monitoring.
13. ICU Discharge Criteria
Delivered, platelet count trending upward (typically nadirs 24-48h postpartum then recovers), LFTs and LDH improving, no evidence of hepatic rupture or ongoing DIC, magnesium course completed (24h postpartum), BP controlled, hemodynamically stable.
14. Documentation & Medicolegal Checklist
15. Key Guidelines
Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981-991.
16. Controversies
The precise platelet count threshold defining HELLP severity classes (some systems use tiered classifications) varies across published classification systems (e.g., Mississippi vs Tennessee classifications), leaving some practice variation in severity grading, though the transfusion thresholds themselves (20K/50K) are more consistently applied. The role of corticosteroids specifically for HELLP-directed treatment (beyond fetal lung maturity indication) has been studied without consistent evidence of maternal benefit, so betamethasone use here should be understood as fetal-benefit-driven, not a HELLP-specific therapeutic intervention.
17. References
- Preeclampsia/Eclampsia/HELLP chapter. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 72).
- Chawla R, Nasa P, Chawla R, Jagiasi BG. Severe Preeclampsia (HELLP section). ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020 (Ch. 20).
- Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981-991.
- Sibai BM. Imitators of severe preeclampsia. Obstet Gynecol. 2007;109:956-966.
See also: Eclampsia (Obstetrics System) for the shared magnesium sulfate, BP management, and fluid strategy framework this protocol builds upon.